New hope for liver cancer patients: 4-drug combo targets untreatable tumors
NCT ID NCT07230314
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a powerful combination of treatments for people with liver cancer that cannot be surgically removed. It combines two local therapies (TACE and SBRT) with an immunotherapy drug and a targeted pill (donafenib) as the first treatment. The goal is to shrink tumors and control the disease. The study involves 34 adults aged 18-75 who have not had prior systemic therapy for their current cancer stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- Immunotherapy combo tested against untreatable liver cancer
- Liver cancer drug combo shows promise in large trial
- New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
- New radioactive beads aim to outperform standard liver cancer therapy